CRINONE® 8% (progesterone gel) is a vaginal progesterone gel utilizing our sustained-release bioadhesive technology indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with a progesterone deficiency. CRINONE was approved by the FDA in May 1997. Columbia sold U.S. rights to CRINONE 8% and CRINONE 4% to Watson Pharmaceuticals, Inc. in July 2010. Merck Serono holds marketing rights to CRINONE 8% for all territories outside of the United States. For more information, please visit Watson's product website www.crinoneusa.com. For patient support, or to report an adverse event, please contact Watson Pharmaceuticals as follows:
CRINONE® is a registered trademark of Watson Pharmaceuticals, Inc.
